StockNews.AI
ABOS
StockNews.AI
152 days

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

1. Acumen to report Q4 and year-end 2024 results on March 27. 2. They are developing a treatment for Alzheimer's targeting amyloid beta oligomers. 3. ACU193 is in Phase 2 trials, following positive Phase 1 results. 4. The company is focused on addressing Alzheimer’s disease pathology. 5. A conference call will provide further insights into financials and plans.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive trial results often boost investor confidence, historically seen in biotech stocks.

How important is it?

The announcement of trial progress and financials is crucial for investor sentiment and stock valuation.

Why Short Term?

Upcoming financial results and conference call can influence stock movement quickly, as seen previously in biopharma announcements.

Related Companies

AMGNBIIBJNJ
March 20, 2025 16:00 ET  | Source: Acumen Pharmaceuticals, Inc. NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.   To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.    The webcast audio will be available via this link. An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.  Investors: Alex Braunabraun@acumenpharm.com Media: AcumenPR@westwicke.com 

Related News